The Effectiveness and Safety of Continuous infusion of Dexmedetomidine during General Anesthesia: A Randomized Controlled trail

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021810

Enrollment

Unknown

Registered

2019-03-11

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Interventions

Experimental Group:Continuous Infusion of Dexmedetomidine

Control group:Continuous Infusion of normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with full ability to communicate undergoing selective operation with general anesthesia, ASA status I-II, aged 18 to 60 years, no restriction on gender, operation time 1-3 hours.

Exclusion criteria

Exclusion criteria: 1. Allergic to dexmedetomidine or any drugs used during this study; 2. Patients on long-term therapy with narcosis analgeticsedative or non-steroid anti-inflammatory drugs; 3. patients with cardiopulmonary disfunction; 4. Patients with allergic disorders; 5. Patients with mental illness; 6. Patients with Cardiac conduction disturbances or allorhythmia HR< 50 bpm, SBP< 100 mmHg.

Design outcomes

Primary

Measure	Time frame
blood pressure;heart rate;NRS scores;hypotension or hypertension;Tachycardia or bradycardia;Nausea and vomiting;pruritus;shiver;	—

Countries

China

Contacts

Public ContactSiyuan Liu

Affiliated Hospital of Nantong University

jssylsy@126.com+86 15806297359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026